Short bioregulator peptide (pineal / CNS research)
EDR peptide
A short peptide studied in pineal and CNS bioregulator research; independent human evidence is limited.
- Evidence:
- Insufficient evidence summarized
- Status:
- Research-stage
- Reviewed:
- 2026-08-03
Also known as: EDR peptide
What is EDR peptide?
A short peptide studied in pineal and CNS bioregulator research; independent human evidence is limited.
This profile is educational. It organizes publicly discussed research context for EDR peptide and related naming aliases — it is not a treatment guide.
Proposed mechanism
Proposed pinealocyte / neuronal gene-expression effects affecting circadian and antioxidant pathways in models.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Insufficient evidence summarized
Preclinical evidence grade: Early-stage human research
Pinealon is part of the short-peptide bioregulator family. Claims around cognition or aging should be treated cautiously.
Key uncertainties
- Human CNS outcomes
Research areas being studied
- Pineal research
- Circadian biology
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Insufficient systematic human data
Additional risks & considerations
- Unproven anti-aging claims
Regulatory status
Research-stage
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is EDR peptide?
A short peptide studied in pineal and CNS bioregulator research; independent human evidence is limited.
How does EDR peptide work (proposed mechanism)?
Proposed pinealocyte / neuronal gene-expression effects affecting circadian and antioxidant pathways in models.
What is EDR peptide being researched for?
EDR peptide has been discussed in research contexts including: Pineal research, Circadian biology.
What does current evidence say about EDR peptide?
Insufficient evidence summarized. Pinealon is part of the short-peptide bioregulator family. Claims around cognition or aging should be treated cautiously.
What safety considerations are noted for EDR peptide?
Reported or discussed considerations include: Insufficient systematic human data; Unproven anti-aging claims. This is educational information, not medical advice.
References & sources
- Khavinson VK et al. (2011). EDR peptide (Pinealon) research overview — Bull Exp Biol Med. Evidence type: review.
Prefer interactive tools? Open the PepGuide library entry for EDR peptide or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.